Global Kaposi Sarcoma Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Kaposi Sarcoma Market was valued at $150 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.5% CAGR, to an estimated market size of $187 mn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Kaposi Sarcoma market encompasses the diagnostic solutions and therapeutic interventions designed to treat a rare cancer originating from the cells lining blood or lymph vessels. The scope includes chemotherapy, highly active antiretroviral therapy (HAART), immunotherapy, and targeted therapies specifically for populations affected by the Kaposi sarcoma-associated herpes virus (KSHV/HHV8), primarily including HIV/AIDS patients, organ transplant recipients, and other immunocompromised individuals.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Kaposi Sarcoma Market in the period 2025-30:
- Wider adoption of pegylated liposomal anthracyclines as a first-line treatment due to reduced cardiotoxicity compared to traditional regimens.
- Increasing incidence of the disease among non-HIV populations, specifically organ transplant recipients and patients on long-term immunosuppressive biologics.
- Advancements in precision medicine and AI-driven pathology are significantly shortening diagnostic lead times for rare subcutaneous manifestations.
- A growing clinical pipeline focused on immune-checkpoint inhibitors like Nivolumab to target the underlying HHV-8 virus in treatment-resistant cases.
- Improved global access to antiretroviral therapies in low- and middle-income countries is creating a larger pool of survivors requiring long-term cancer surveillance.
- The entry of generic formulations following patent expiries of major chemotherapy agents is improving treatment affordability in developing regions.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
Segments
- Chemotherapy
- Antiviral Therapy (HAART)
- Immunotherapy & Targeted Therapy
- Others